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Mannheim, GermanyBackground: Acute GI bleeding remains a clinical problem of daily importance. Increasing numbers of patients
with compromised coagulation challenge the established methods of endoscopic hemostasis. Therefore, new
powders for the treatment of GI bleeding have been developed.
Objective: To clarify the efﬁcacy of a newly available anticoagulant powder in stopping hemorrhage.
Design: A randomized prospective comparative study regarding the potential of an endoscopically applicable
polysaccharide powder in pigs receiving antithrombotic medication.
Setting: A professional veterinary animal laboratory.
Patients: Twenty-two pigs were anticoagulated with heparin (n Z 8), aspirin (n Z 8), or no antithrombotic
medication (n Z 6), in a randomized order.
Interventions: A bleeding ulcer with continuous bleeding (Forrest I b) was established in the stomach. Endo-
scopic hemostasis was performed using the powder.
Main Outcome Measurements: Time to hemostasis and the amount of powder used were recorded.
Follow-up occurred for 3 days, ﬁnal hemoglobin measurement, followed by autopsy with control for post-
interventional bleeding.
Results: Endoscopic hemostasis was successful in all cases. Post-interventional bleeding was not recorded.
Limitations: Animal study, artiﬁcial superﬁcial bleeding source.
Conclusion: Polysaccharide powder is able to stop active bleeding from Forrest I b lesions in pigs receiving
antithrombotic therapy.The frequency of acute GI bleeding is estimated to be
between 48 and 160 per 100,000 adults per year.1 The
increasing numbers of patients receiving antithrombotic
therapy (ATT) challenge the established methods of endo-
scopic hemostasis. Despite major advances in endoscopic
methods, mortality still remains high. One explanation
for this is the growing number of patients with signiﬁcant
comorbidity and current ATT.n: ATT, antithrombotic therapy.
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from the GIE website or by using
the QR code and your mobile de-
vice. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
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urnal.orgAgainst this background, new powders for the endo-
scopic treatment of GI bleeding have come onto the market
in recent years.2-4 Most of the available data describe
clinical results without reference to the coagulation system.
Because the value of these new agents in anticoagulated
individuals is still unclear, we conducted a randomized
prospective comparative study regarding the potential of
an endoscopically applicable polysaccharide powder.article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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TABLE 1. Comparison of animals with and without antithrombotic therapy
All (n [ 22) Aspisol (n [ 8) Heparin (n [ 8) Control (n [ 6) P value
Median weight, kg (range) 26.2 (19-39) 24.7 (20.4-29) 25.6 (19-35) 28.2 (20-39)
Median no. of EndoClot applications (range) 2.54 (1-5) 2.75 (2-5) 2.88 (2-4) 2 (1-4) .245198566
Median amount of EndoClot for hemostasis, g (range) 3.42 (2-8) (2-8) 3.75 (2-8) 2.5 (2-4) .161118995
Median time until hemostasis, min (range) 09:41 (2:08-23:00) 10:39 (3:50-20:35) 11:30 (2:45-23:00) 05:15 (2:08-10:20) .055957075
Endoscopic application of polysaccharide powder for hemostasis Kaehler et alMETHODS
To compare the effectiveness of the polysaccharide
powder in pigs with and without ATT, we performed
a prospective randomized comparative study in 22
minipigs. The study was approved by the local animal pro-
tection committee (Thüringer Landesamt für Lebens-
mittelsicherheit und Verbraucherschutz no. 08-003/11).
Main outcome parameters were hemostasis, the time to
achieve hemostasis, and the amount of powder to achieve
hemostasis.
Eight pigs were treated with aspisol (250 mg aspi-
rin intravenously; Bayer Health Care AG, Leverkusen, Ger-
many), 8 received heparin (200 international units heparin-
natrium/kg body weight; Ratiopharm GmbH, Ulm, Ger-
many), and 6 served as controls. The tests were performed
in a randomized order. After establishing general anes-
thesia with tracheal intubation, a standard EGD with a ther-
apeutic gastroscope (GIF-2TH180 Evis Exera II; Olympus
GmbH Medical Systems, Hamburg, Germany) was carried
out. The endoscopist (G.K.) was blinded regarding pre-
treatment with ATT. A 20-mm bleeding ulcer in the major
curve of the gastric corpus was then created by a “cold
snare” removal of approximately 2 cm2 using a standard
polypectomy snare (30 mm POL1-B1-30-23-220-OL; Med-
work GmbH, Höchstadt, Aisch, Germany). This lesion
with active bleeding was regarded as a Forrest I b
equivalent.
The lesion was treated with 2 g EndoClot (EndoClot
Plus Inc, Santa Clara, Calif.). The powder was applied
with strict avoidance of any ﬂuid reﬂux to the catheter
system until the bleeding had stopped (Video 1, available
online at www.giejournal.org). The ulcer site was
observed for a minimum of 2 minutes; if further bleeding
occurred, the site was washed with an Endo-Washer (AFU-
100; Olympus GmbH Medical Systems) to remove blood
and powder remnants. The procedure was repeated until
a permanent hemostasis was achieved. Finally, blood and
other ﬂuids were removed from the stomach by suction.
Hemoglobin was measured before and after the
procedure.
After extubation, the pigs were returned to their stable
with a ﬂuid intake during the same day and normal food
from postoperative day 1. They were observed for behavior
and nutrition uptake. On postoperative day 3, their hemo-
globin measurement was repeated, after which they were162 GASTROINTESTINAL ENDOSCOPY Volume 82, No. 1 : 2015killed. The autopsy followed a protocol with inspection
for any bloody content of the peritoneum, stomach, and
small and large bowel. The absence of blood throughout
the entire intestinal tract indicated they could be classiﬁed
as having no sign of further GI bleeding.
Statistical analysis was performed using the t test. The
level of statistical signiﬁcance was set at P! .05.RESULTS
Endoscopic hemostasis could be achieved with Endo-
Clot alone in all cases with a mean application of 3.42 g
polysaccharide powder (range, 2-8; median, 3). The appli-
cation time was a mean of 9:41 minutes (range, 2:08-23:00;
median, 9:55).
In the heparin group the application time was a mean
of 11:30 minutes (range, 2:45-23:00; median, 10:55), in
the aspisol group 10:39 minutes (range, 3:50-20:35; me-
dian, 10:05), and in the control group 5:15 minutes (range,
2:08-10:20; median, 3:32). The amount of powder needed
to achieve complete hemostasis was 3.75 g (range, 2-8;
mean, 3.5) in the heparin group, 4.0 g (range, 2-8; mean,
3.5) in the aspisol group, and 2.5 g (range, 2-4; mean,
2.0) in the control group (Table 1).
The differences between the ATT groups and the
controls were not statistically signiﬁcant because of
the high variance. No post-interventional bleeding was
recorded, and hemoglobin measurements showed no
decrease.DISCUSSION
Patients at risk of thromboembolic adverse events place
the physician in a therapeutic dilemma. It is known that
ATT, especially double medications, elevate the risk of GI
bleeding.5,6 Many patients after cardiologic or cardiosurgi-
cal interventions receive a combination of different drugs
to prevent hazardous thromboembolic events. Thus, endo-
scopic treatment of acute GI bleeding is increasingly
needed by these patients. Consequently, we see a need
for hemostatic methods that work independently from
physiologic coagulation.
Organic powders have been found to achieve immedi-
ate hemostasis in different ﬁelds of surgery. Derived
from puriﬁed plant starch, EndoClot is a powder with awww.giejournal.org
Kaehler et al Endoscopic application of polysaccharide powder for hemostasismolecular structure of modiﬁed polysaccharides. Its active
principle is rapid water absorption from the blood. The
following dehydration process leads to a high concentra-
tion of platelets, red blood cells, and coagulation proteins
(thrombin, ﬁbrinogen, etc) that accelerate the normal
physiologic clotting cascade. Polysaccharide powder was
found to be effective in the support of wound healing
and in thoracic and vascular surgery.3,4,7 These encour-
aging results suggest the possibility of endoscopic applica-
bility of these hemostatic powders. Related to the
enormous absorption capability of the powder, it is crucial
to develop an application technique that avoids a reﬂux of
any ﬂuid to the application system.
Two systems for endoscopic application of such powders
are available: Hemospray (Wilson-Cook Medical Inc,Winston-
Salem, NC) and EndoClot.2-4,7 Several case series report the
applicability and efﬁcacy of Hemospray for bleeding lesions
and for Endo-Clot in the prevention of bleeding after EMR.3
Except for Holster et al,2 reporting on 8 patients with ATT
and upper GI bleeding treated successfully with Hemospray
in 5 of 8 patients, data are lacking about the function of he-
mostatic powders in anticoagulated individuals. We therefore
conducted this comparative study to clarify the potential of
EndoClot in the treatment of bleeding GI lesions under con-
ditions of ATT. It is remarkable that hemostatic powders are
regarded as technical products from a legal point of view.
This may explain how these products came onto the market
without comprehensive data about their indications and con-
traindications, as would be seen in pharmacologic products.
The minipig is generally accepted as a good animal
model to simulate GI diseases and their endoscopic man-
agement. The application of aspisol for platelet aggrega-
tion inhibition and heparin for the reduction of plasmatic
coagulation represents both basic types of coagulation dis-
orders. The dosage used was found to be active in previous
tests from our team.8 In that series the same dosage
caused spontaneous bleeding, which was not observed in
this series.
The experimental model used to create mucosal ulcers
by snaring without electrical current mimics superﬁcialwww.giejournal.orglesions and bleeding sources. Therefore, the results of
this study cannot be applied for arterial bleeding like
Forrest I a. We found that EndoClot was able to stop the
simulated Forrest I b lesions in every case. The expendi-
ture, represented by the amount of powder and the time
needed to achieve compete hemostasis, did not differ
signiﬁcantly (Table 1). These results are not surprising
considering the principle on how these powders act. For
users of hemostatic powders in anticoagulated patients, it
is important to know they should expect a longer applica-
tion time and may need to repeat the applications until
complete hemostasis occurs.
In conclusion, polysaccharide powder (EndoClot) is
able to stop active (nonarterial) bleeding from Forrest I b
lesions in pigs receiving ATT. It is a new option for the
endoscopic treatment of superﬁcial GI bleeding in ATT pa-
tients. To conﬁrm these experimental data, clinical studies
are warranted.
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